These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1358 related items for PubMed ID: 16703222

  • 21. Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.
    Miyagi S, Sekiguchi S, Kawagishi N, Akamatsu Y, Satoh K, Takeda I, Fukushima D, Kobayashi Y, Tokodai K, Fujimori K, Satomi S.
    Transplant Proc; 2011 Nov; 43(9):3299-301. PubMed ID: 22099782
    [Abstract] [Full Text] [Related]

  • 22. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M, Desai DM, Cox KL, Berquist WE, Esquivel CO, Millan MT.
    Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
    [Abstract] [Full Text] [Related]

  • 23. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder.
    Ganne V, Siddiqi N, Kamaplath B, Chang CC, Cohen EP, Bresnahan BA, Hariharan S.
    Clin Transplant; 2003 Oct; 17(5):417-22. PubMed ID: 14703923
    [Abstract] [Full Text] [Related]

  • 24. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.
    Younes BS, McDiarmid SV, Martin MG, Vargas JH, Goss JA, Busuttil RW, Ament ME.
    Transplantation; 2000 Jul 15; 70(1):94-9. PubMed ID: 10919581
    [Abstract] [Full Text] [Related]

  • 25. Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients.
    Smith JM, Corey L, Healey PJ, Davis CL, McDonald RA.
    Transplantation; 2007 Jun 15; 83(11):1423-8. PubMed ID: 17565314
    [Abstract] [Full Text] [Related]

  • 26. Risk factors and clinical outcomes of pediatric liver transplant recipients with post-transplant lymphoproliferative disease in a multi-ethnic Asian cohort.
    Huang JG, Tan MYQ, Quak SH, Aw MM.
    Transpl Infect Dis; 2018 Feb 15; 20(1):. PubMed ID: 29071779
    [Abstract] [Full Text] [Related]

  • 27. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
    Sokal EM, Antunes H, Beguin C, Bodeus M, Wallemacq P, de Ville de Goyet J, Reding R, Janssen M, Buts JP, Otte JB.
    Transplantation; 1997 Nov 27; 64(10):1438-42. PubMed ID: 9392308
    [Abstract] [Full Text] [Related]

  • 28. Abdominal involvement in pediatric heart and lung transplant recipients with posttransplant lymphoproliferative disease increases the risk of mortality.
    Tai CC, Curtis JL, Szmuszkovicz JR, Horn MV, Ford HR, Woo MS, Wang KS.
    J Pediatr Surg; 2008 Dec 27; 43(12):2174-7. PubMed ID: 19040929
    [Abstract] [Full Text] [Related]

  • 29. Outcomes of kidney retransplantation in recipients with prior post-transplant lymphoproliferative disorder.
    Rouphael B, Lankireddy S, Lazaryan A, Kukla A, Ibrahim HN, Matas AJ, Issa N.
    Clin Transplant; 2016 Jan 27; 30(1):60-5. PubMed ID: 26497471
    [Abstract] [Full Text] [Related]

  • 30. Primary central nervous system posttransplantation lymphoproliferative disorder after heart and lung transplantation.
    Gifford G, Fay K, Jabbour A, Ma DD.
    Intern Med J; 2015 May 27; 45(5):583-6. PubMed ID: 25955465
    [Abstract] [Full Text] [Related]

  • 31. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression.
    Ellis D, Jaffe R, Green M, Janosky JJ, Lombardozzi-Lane S, Shapiro R, Scantlebury V, Vivas C, Jordan ML.
    Transplantation; 1999 Oct 15; 68(7):997-1003. PubMed ID: 10532541
    [Abstract] [Full Text] [Related]

  • 32. Posttransplant lymphoproliferative disorder after liver and kidney transplant.
    Akar Özkan E, Özdemir BH, Deniz EE, Tunca MZ, Haberal M.
    Exp Clin Transplant; 2014 Mar 15; 12 Suppl 1():142-8. PubMed ID: 24635813
    [Abstract] [Full Text] [Related]

  • 33. Posttransplant Lymphoproliferative Disorders in Irish Renal Transplant Recipients: Insights From a National Observational Study.
    OʼRegan JA, Prendeville S, McCaughan JA, Traynor C, OʼBrien FJ, Ward FL, OʼDonovan D, Kennedy C, Berzan E, Kinsella S, Williams Y, OʼKelly P, Deady S, Comber H, Leader M, Conlon PJ.
    Transplantation; 2017 Mar 15; 101(3):657-663. PubMed ID: 27214265
    [Abstract] [Full Text] [Related]

  • 34. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression.
    Newell KA, Alonso EM, Whitington PF, Bruce DS, Millis JM, Piper JB, Woodle ES, Kelly SM, Koeppen H, Hart J, Rubin CM, Thistlethwaite JR.
    Transplantation; 1996 Aug 15; 62(3):370-5. PubMed ID: 8779685
    [Abstract] [Full Text] [Related]

  • 35. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J, Gil L, Tridello G, Ljungman P, Donnelly JP, van der Velden W, Omar H, Martino R, Halkes C, Faraci M, Theunissen K, Kalwak K, Hubacek P, Sica S, Nozzoli C, Fagioli F, Matthes S, Diaz MA, Migliavacca M, Balduzzi A, Tomaszewska A, Camara Rde L, van Biezen A, Hoek J, Iacobelli S, Einsele H, Cesaro S, Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Clin Infect Dis; 2013 Sep 15; 57(6):794-802. PubMed ID: 23771985
    [Abstract] [Full Text] [Related]

  • 36. [Clinicopathologic study of post-transplant lymphoproliferative disorders].
    Zhang YN, Zhou XG, Wang CZ, Wei P, Zhang SH, Zheng YY.
    Zhonghua Bing Li Xue Za Zhi; 2006 Apr 15; 35(4):209-12. PubMed ID: 16776977
    [Abstract] [Full Text] [Related]

  • 37. Managing the challenge of PTLD in liver and bowel transplant recipients.
    Lauro A, Arpinati M, Pinna AD.
    Br J Haematol; 2015 Apr 15; 169(2):157-72. PubMed ID: 25377273
    [Abstract] [Full Text] [Related]

  • 38. Post-transplantation lymphoproliferative disorder in pediatric kidney-transplant recipients - a national study.
    Cleper R, Ben Shalom E, Landau D, Weissman I, Krause I, Konen O, Rahamimov R, Mor E, Bar-Nathan N, Frishberg Y, Davidovits M.
    Pediatr Transplant; 2012 Sep 15; 16(6):619-26. PubMed ID: 22708682
    [Abstract] [Full Text] [Related]

  • 39. Post-Transplant Lymphoproliferative Diseases in Pediatric Kidney Allograft Recipients with Epstein-Barr Virus Viremia.
    Hyun H, Park E, Cho M, Min SI, Ha J, Kang HJ, Shin HY, Ha IS, Cheong HI, Ahn YH, Kang HG.
    J Korean Med Sci; 2019 Aug 05; 34(30):e203. PubMed ID: 31373185
    [Abstract] [Full Text] [Related]

  • 40. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
    Rabot N, Büchler M, Foucher Y, Moreau A, Debiais C, Machet MC, Kessler M, Morelon E, Thierry A, Legendre C, Rivalan J, Kamar N, Dantal J.
    Transpl Int; 2014 Sep 05; 27(9):956-65. PubMed ID: 24964147
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 68.